Bayer and Hologic collaborate to deliver contrast-enhanced-mammography solutions to improve the detection of breast cancer
Bayer and Hologic, Inc., announced an international partnership to deliver contrast-enhanced-mammography (CEM) solutions to improve the detection of breast cancer in multiple countries across Canada, the European and Asia Pacific regions
CEM is an innovative highly sensitive and low-cost breast imaging modality which combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions. The partnership brings together the companies’ leading technologies (Hologic mammography gantries and Bayer CEM approved injection systems), which enable accurate administration of contrast media during a mammography examination. Bayer and Hologic aim to optimally support radiologists and their teams to effectively implement CEM seamlessly into a radiologist’s workflow.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins